FDA gives the green signal for Abbott’s finger prick-free blood sugar proportion monitoring device
Date: 2017-09-29   Author: Dhananjay Punekar  Category: #news

The U.S. Food and Drug Administration (FDA) has officially approved the FreeStyle Libre, a bottle cap-sized wearable sensor device developed by Abbot laboratories, a U.S. based healthcare firm, to continuously check the glucose levels in diabetic patients. As per reliable sources, the equipment is water-resistant and can be efficiently worn while swimming as well. It is also equipped with advanced technology that eliminates the need for daily finger pricking and can be easily scanned over fabrics & clothes.  In addition, the equipment comprises a small reader that scans the sensor, gathers real-time data about the glucose levels in the patient, and examines the sugar level measurements taken during the last eight hours. Abbot’s move has been touted to prove highly beneficial for the healthcare fraternity.

Earlier in 2016, FDA had approved a similar type of product introduced by the Dexcom Incorporation, a medical device manufacturing firm based in the U.S. Unlike Abbot’s freestyle Libre, however, the tool was supposed to be calibrated with a finger prick two times in a day to measure the glucose levels in the diabetics, which is where Abbot’s equipment takes an upper hand. After receiving the approval for its wearable sensor equipment, Abbott’s shares depicted a rise of 3.6%, closing at USD 54 per share, while Dexcom’s shares plunged to 34%, cite sources.

If reports are to be believed, the cost of the wearable sensor Libre in the U.S. will be equivalent to its costs across Europe. At present, the sensor & reader cost around USD 140 for a single patient in Europe and necessitates replacement every ten days. The yearly cost amounts to USD 1900 across the region, which also encompasses the price of one reader and twenty-six sensors.

The U.S. houses close to 30 million diabetic patients, many among which are reported to be using standard glucose monitoring devices that require multiple finger pricking. In addition, these devices display only the current glucose level in the patients. Abbott’s freestyle Libre device, on the other hand, helps in continuously monitoring the glucose levels in the patients, which would undoubtedly prove to be highly beneficial for diabetic patients. Experts cite that the device is likely to substantially impact the product landscape of the United States medical device market in the forthcoming years.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Australia to ban Huawei’s participation in 5G mobile telecom rollout
Author: Dhananjay Punekar

In a major blow to China-Australia relations, Australia is planning to exclude Huawei from the list of participants invited for the 5G mobile telecom rollout in the country. Reportedly, the country fears that the Chine...


Siemens pioneers facility to use ammonia for renewable energy storage
Author: Dhananjay Punekar

Siemens AG, a German firm headquartered in Munich, has inaugurated a £1.5 million pilot venture in Oxfordshire, with an aim to promoting the use of ammonia as a new kind of energy storage. Reportedly, the firm wa...


Shell offers engineering contract to Subsea 7 for Penguins Project
Author: Dhananjay Punekar

Royal Dutch Shell PLC, a renowned oil & gas firm, has offered Subsea 7 S.A., a UK based engineering, construction, and services firm, a contract for the redevelopment of its Penguins oil & gas field located in ...